Trial Information
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Sponsor: Gilead Sciences, Inc. Immunomedics
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
